SCHEMBL6466

SCHEMBL6466

O=S(=O)(O)Cc1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.43
ERBB2 P04626 4/20 0.43
PLCG1 P19174 1/20 0.43
CA2 P00918 3/20 0.40
CA1 P00915 2/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
NPC1 O15118 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR2A P28223 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2A6 P11509 1/20 0.38
IDO1 P14902 2/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3616094 0.98 EGFR (0.42) EGFRERBB2PLCG1CA2CA1
SCHEMBL9000869 0.98 EGFR (0.42) EGFRERBB2PLCG1CA2CA1
SCHEMBL8474031 0.87 CA2 (0.41) CA2CA1MMP1MMP2MMP9
SCHEMBL9200717 0.80 PLCG1 (0.46) EGFRERBB2PLCG1CA2CA1
SCHEMBL1138688 0.80 PLCG1 (0.46) EGFRERBB2PLCG1CA2CA1
SCHEMBL259654 0.78 CA2 (0.52) CA2CA1MMP1MMP2MMP9
SCHEMBL4371994 0.78 ABAT (0.50) CA2CA1TAAR1IDO1CA12
SCHEMBL3134989 0.77 TAAR1 (0.46) EGFRERBB2PLCG1CA2CA1
SCHEMBL24407431 0.76 IDO1 (0.42) CA2CA1MMP1MMP2MMP9
SCHEMBL2336520 0.76 CA1 (0.34) CA2CA1MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926327-B2 Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds ZOETIS SERVICES LLC (US) 2018-03-27 US claimed
US-20250020997-A1 PHOTORESIST COMPOSITIONS AND METHODS OF MANUFACTURING INTEGRATED CIRCUIT DEVICES USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-01-16 US disclosed
EP-3416965-B1 PROCESS FOR PREPARING 7H-PYRROLO [2,3-D]PYRIMIDINE COMPOUNDS ZOETIS SERVICES LLC (US) 2020-10-07 EP disclosed
EP-3416965-A1 PROCESS FOR PREPARING 7H-PYRROLO [2, 3-D]PYRIMIDINE COMPOUNDS Zoetis Services LLC (US) 2018-12-26 EP disclosed
EP-2976340-B1 CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-06-13 EP disclosed
US-9926327-B2 Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds ZOETIS SERVICES LLC (US) 2018-03-27 US disclosed
US-9926327-B2 Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds ZOETIS SERVICES LLC (US) 2018-03-27 US disclosed
WO-2017142740-A1 PROCESS FOR PREPARING 7H-PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS ZOETIS SERVICES LLC (US) 2017-08-24 WO disclosed
WO-2017142740-A1 PROCESS FOR PREPARING 7H-PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS ZOETIS SERVICES LLC (US) 2017-08-24 WO disclosed
US-20170233397-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS ZOETIS SERVICES LLC 2017-08-17 US disclosed
EP-0708760-A1 CYCLIC HYDRAZINE COMPOUNDS Novartis AG (CH) 1996-05-01 EP disclosed
WO-1995002582-A1 CYCLIC HYDRAZINE COMPOUNDS CIBA-GEIGY AG (CH) 1995-01-26 WO disclosed
US-5279899-A Metal coated polyamide having a sulfonate containing compound at interface MONSANTO COMPANY (US) 1994-01-18 US disclosed
WO-1993019239-A1 SULFONATED POLYAMIDES MONSANTO COMPANY (US) 1993-09-30 WO disclosed
US-4598076-A 2-pyrrolin-3-carbonitril-derivatives, pharmaceutical compositions containing them and their anti-inflammatory and ulcer protective activity WARNER-LAMBERT COMPANY (US) 1986-07-01 US disclosed
EP-0091045-B1 2-PYRROLINE-3-CARBONITRILE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM GÖDECKE AKTIENGESELLSCHAFT (DE) 1986-02-26 EP disclosed
US-4517185-A 2-Pyrrolin-3-carbonitrile derivatives, and pharmaceutical compositions containing them and their anti-inflammatory and ulcer protective activity WARNER-LAMBERT COMPANY (US) 1985-05-14 US disclosed
US-4208351-A Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor ELI LILLY AND COMPANY (US) 1980-06-17 US disclosed
US-4176233-A Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor ELI LILLY AND COMPANY (US) 1979-11-27 US disclosed
US-4102902-A Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor ELI LILLY AND COMPANY (US) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233397-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS TPMT, TYMS, TYMP EGFR 4615/4885ERBB2 3586/4885PLCG1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.